Prospects for new antitubercular drugs.
Duncan
Ken
K
GlaxoSmithKline, Gunnels Wood Road, Stevenage, SG1 2NY, UK. ken.5.duncan@gsk.com
Barry
Clifton E
CE
D000818:Animals; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D015363:Quinolones / Q000494:pharmacology / Q000627:therapeutic use; D012294:Rifamycins / Q000494:pharmacology / Q000627:therapeutic use; D014376:Tuberculosis / Q000188:drug therapy* / Q000453:epidemiology
D000995:Antitubercular Agents; D015363:Quinolones; D012294:Rifamycins